Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Physical Review Letters|April 19, 2024
Anomalous Resistivity and Electron Heating by Lower Hybrid Drift Waves during Magnetic Reconnection with a Guide FieldJongsoo Yoo, Jonathan Ng, Hantao Ji, et al.
Oncoimmunology|February 7, 2019
APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapyAmélie Boichard, Timothy V Pham, Huwate Yeerna, et al.
Oncotarget|July 2, 2019
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinomaCelina Ang, Samuel J Klempner, Siraj M Ali, et al.
Annals of the Entomological Society of America|January 22, 2026
Evaluating perceptions of STEM majors to explain diversity gaps in entomology and other sciencesDominic A Evangelista, Melissa Sanchez-Herrera, Johanna Schwartz, et al.
British Journal of Haematology|December 10, 2022
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysisTommy Etekal, Kelly Koehn, Douglas W Sborov, et al.
JAMA Network Open|November 10, 2023
Adverse Event Reporting in Randomized Clinical Trials for Multiple MyelomaMimi Najjar, John McCarron, Edward R Scheffer Cliff, et al.
Cancers|December 26, 2018
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical TrialsNatalie Galanina, Rafael Bejar, Michael Choi, et al.
Oncoimmunology|March 3, 2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneityShumei Kato, Ryosuke Okamura, Yuichi Kumaki, et al.
Journal of the National Cancer Institute|March 2, 2024
Dietary interventions in cancer: a systematic review of all randomized controlled trialsNosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, et al.
JCO Precision Oncology|May 7, 2019
Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced MalignanciesShumei Kato, Ryosuke Okamura, Manvita Mareboina, et al.
Pageof 5